Commentary|Podcasts|November 19, 2025

Pharma Pulse: Patients Struggle to Identify Safe Online Pharmacies, as Novo Nordisk Launches Access Offers

In today’s Pharma Pulse, learn how digital pharmacy safety gaps, Novo Nordisk’s introductory programs for Wegovy and Ozempic, and Scott Gottlieb’s new role at UnitedHealth are shaping patient access and industry strategy.

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and let’s get into today’s headlines.

  • A recent survey reveals that while half of patients have used online pharmacies, fewer than 10% can reliably identify safe and legitimate sites. Experts warn that this knowledge gap exposes patients to potential counterfeit drugs and underscores the need for stronger consumer education and verification tools in digital pharmacy access.
  • Novo Nordisk is rolling out introductory offers for its weight management and diabetes therapies, Wegovy and Ozempic. The program aims to increase patient access and encourage adherence amid growing interest in GLP-1 therapies. The company emphasizes that these offers are designed to help patients start treatment while navigating cost and insurance challenges.
  • In corporate news, former FDA Commissioner Scott Gottlieb has joined the board of directors at UnitedHealth. His experience in regulatory oversight and healthcare policy is expected to inform the insurer’s strategic direction, particularly in navigating evolving drug pricing, access, and innovation challenges.

That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit pharmaceuticalcommerce.com.

Thanks for listening—until next time, stay well and stay informed.

You can catch Pharma Pulse directly on AudioboomSpotify, or iHeart.

Newsletter

Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.